Emotional and Neuropsychiatric Disorders Associated with Alzheimer's Disease

被引:20
作者
Heilman, Kenneth M. [1 ,3 ,4 ,5 ]
Nadeau, Stephen E. [2 ,3 ,4 ,5 ]
机构
[1] Malcom Randall VA Med Ctr, Geriatr Res Educ & Clin Ctr, 1601 SW Archer Rd, Gainesville, FL 32608 USA
[2] Malcom Randall VA Med Ctr, Res Serv, 1601 SW Archer Rd, Gainesville, FL 32608 USA
[3] Malcom Randall VA Med Ctr, Brain Rehabil Res Ctr, 1601 SW Archer Rd, Gainesville, FL 32608 USA
[4] Univ Florida, Coll Med, Malcom Randall VA Med Ctr, Gainesville, FL 32611 USA
[5] Univ Florida, Coll Med, Dept Neurol, Gainesville, FL 32611 USA
关键词
Alzheimer's disease; Emotional facial expression; Emotional prosody; Alexithymia; Agitation; aggression; Depression; Psychosis; Sleep disorders; ATYPICAL ANTIPSYCHOTIC MEDICATIONS; PLACEBO-CONTROLLED TRIAL; DOUBLE-BLIND; PSYCHOLOGICAL SYMPTOMS; BEHAVIORAL DISTURBANCES; OLDER-ADULTS; NONPHARMACOLOGICAL INTERVENTIONS; CHOLINESTERASE-INHIBITORS; COGNITIVE IMPAIRMENT; DIAGNOSTIC-CRITERIA;
D O I
10.1007/s13311-021-01172-w
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Alzheimer's disease is associated with impairments in emotional communication including comprehension and production of facial emotional expressions, comprehension of affective prosody, and alexithymia. It is also associated with disorders of emotional experience including mood disorders (depression and anxiety), agitation/aggression, and psychosis. Agitation/aggression and psychosis are particularly disruptive, are associated with earlier institutionalization, and pose a major challenge to institutional management. Treatment of disorders of emotional experience has been primarily pharmacologic (reviewed here in detail) and has relied heavily on antipsychotic medications despite the small effect sizes demonstrated in a large number of randomized controlled trials and the prevalence of serious side effects associated with these drugs. Recent studies suggest that treatment with pimavanserin, an antipsychotic without activity at dopamine receptors, may represent an important advance for treatment of psychotic manifestations, even as the drug appears to pose significant risk. Dextromethorphan/quinidine may represent an important advance in the treatment of agitation/aggression. There is also compelling evidence that sleep disorders, which are common among patients with Alzheimer's disease and are readily treatable, may potentiate psychotic manifestations and agitation/aggression, but further studies are needed.
引用
收藏
页码:99 / 116
页数:18
相关论文
共 50 条
  • [21] Longitudinal Neuropsychiatric Predictors of Death in Alzheimer's Disease
    Spalletta, Gianfranco
    Long, Jeffrey D.
    Robinson, Robert G.
    Trequattrini, Alberto
    Pizzoli, Sonia
    Caltagirone, Carlo
    Orfei, Maria D.
    JOURNAL OF ALZHEIMERS DISEASE, 2015, 48 (03) : 627 - 636
  • [22] Neuropsychiatric assessment of Alzheimer’s disease and related dementias
    J. L. Cummings
    S. McPherson
    Aging Clinical and Experimental Research, 2001, 13 : 240 - 246
  • [23] The Neuropsychiatric Inventory Scores Change Across the Mini Mental State Examination Ranges in Patients With Alzheimer's Disease: A Multicenter Study in Turkey
    Yener, Goersev G.
    COGNITIVE AND BEHAVIORAL NEUROLOGY, 2009, 22 (04) : 264 - 269
  • [24] Anatomical Correlates of the Neuropsychiatric Symptoms in Alzheimer's Disease
    Hu, Xiaochen
    Meiberth, Dix
    Newport, Beate
    Jessen, Frank
    CURRENT ALZHEIMER RESEARCH, 2015, 12 (03) : 266 - 277
  • [25] A controlled clinical trial on the effects of exercise on neuropsychiatric disorders and instrumental activities in women with Alzheimer's disease
    Nascimento, Carla M. C.
    Teixeira, Camila V. L.
    Gobbi, Lilian T. B.
    Gobbi, Sebastiao
    Stella, Florindo
    BRAZILIAN JOURNAL OF PHYSICAL THERAPY, 2012, 16 (03) : 197 - 204
  • [26] Neuropsychiatric symptoms associated multimodal brain networks in Alzheimer's disease
    Li, Kaicheng
    Zeng, Qingze
    Luo, Xiao
    Qi, Shile
    Xu, Xiaopei
    Fu, Zening
    Hong, Luwei
    Liu, Xiaocao
    Li, Zheyu
    Fu, Yanv
    Chen, Yanxing
    Liu, Zhirong
    Calhoun, Vince D.
    Huang, Peiyu
    Zhang, Minming
    HUMAN BRAIN MAPPING, 2023, 44 (01) : 119 - 130
  • [27] Neuropsychiatric Issues in Parkinson's Disease
    Cooney, Jeffrey W.
    Stacy, Mark
    CURRENT NEUROLOGY AND NEUROSCIENCE REPORTS, 2016, 16 (05)
  • [28] Big Data Analysis of Genes Associated With Neuropsychiatric Disorders in an Alzheimer's Disease Animal Model
    Ham, Suji
    Kim, Tae K.
    Hong, Heeok
    Kim, Yong S.
    Tang, Ya-Ping
    Im, Heh-In
    FRONTIERS IN NEUROSCIENCE, 2018, 12
  • [29] Risk Factors, Neuroanatomical Correlates, and Outcome of Neuropsychiatric Symptoms in Alzheimer's Disease
    Poulin, Stephane P.
    Bergeron, David
    Dickerson, Bradford C.
    JOURNAL OF ALZHEIMERS DISEASE, 2017, 60 (02) : 483 - 493
  • [30] Nicotinic treatment for degenerative neuropsychiatric disorders such as Alzheimer's disease and Parkinson's disease
    Rusted, JM
    Newhouse, PA
    Levin, ED
    BEHAVIOURAL BRAIN RESEARCH, 2000, 113 (1-2) : 121 - 129